Introduction Symptomatic bradycardia treatment is based on the transvenous method of endocardial pacing. However, cardiac electronic implantable devices (CEID) are associated with a potential risk of complications, including infections, with an estimated rate of 0.5% with primary implants and 1–7 % with secondary interventions. CIED infections are associated with longer hospital length of stay, higher clinical costs and mortality rates. , According to guidelines, infective endocarditis related to CIED implicates complete removal of the system, followed by a period without […]